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Key to antimicrobial stewardship success: Surveillance by 
diagnostic microbiology laboratories
The important role of laboratories in enhancing 
antimicrobial stewardship activities through improved 
diagnostics and provision of surveillance data is globally 
recognised.[1] Consider the aim of an antimicrobial 
stewardship programme: ‘optimize clinical outcomes 
while minimizing the unintended consequences of antimicrobial use’.
[2] The clinical microbiology laboratory plays a critical role in achieving 
these aims through the provision of culture and susceptibility data 
that are both patient­specific (optimisation of clinical outcomes) and 
informative for surveillance activities that guide empirical antimicrobial 
selection (minimising unintended consequences of antimicrobial use). 
For this reason, the World Health Organization (WHO) included the 
strengthening of surveillance and laboratory capacity in its 2011 
World Health Day six­point plan to combat antimicrobial resistance 
(AMR).[3] South African laboratories in the public and private sectors 
have the means to provide surveillance data and, through a collaborative 
approach, the capacity to create antimicrobial resistance maps. In line 
with the WHO’s recommendations and under the auspices of the South 
African Society of Clinical Microbiology, efforts are currently underway 
to improve national AMR surveillance data for typical healthcare­
associated pathogens. The generation and provision of these data is, 
however, only half of the challenge. The analysis and interpretation 
thereof is equally important, as highlighted in this month’s SAMJ by 
McKay and Bamford[4] in their study comparing community­ with 
healthcare­acquired bloodstream infections at Groote Schuur Hospital 
(GSH), Cape Town, a tertiary public sector hospital.
The study is a retrospective description of bloodstream isolates 
submitted to the GSH laboratory over a 1­year period. Using 
predefined criteria, the isolates were classified as community or 
healthcare acquired and a comparative analysis of resistance patterns 
was undertaken. The issue of differing resistance patterns in the 
community v. hospital is a well­established and much­publicised 
phenomenon.[5] The article serves to reinforce these established 
differences, highlighting the profound resistance associated with 
hospital pathogens: (i) a 47.6% difference in the methicillin­
resistant Staphylococcus aureus (MRSA) rate; and (ii) a ~35% 
difference in extended­spectrum β­lactamase (ESBL) production 
by Enterobacteriaceae. The authors have provided substantive local 
surveillance data to support their recommendations for empirical 
antimicrobial prescribing based on an assessment of whether the 
infection is community or healthcare acquired. They have therefore 
highlighted a crucial element that, for various reasons relating to 
surveillance capacity, has unfortunately not been available in similar 
published local AMR surveillance data.[6­8] This element is the clinical 
and epidemiological context that is required for interpretation of the 
data. Unfortunately without this context the data become blurred and 
the issue of resistance is magnified disproportionately. Aggregated 
data (which is what we have seen to date) give an indication of 
whether overall resistance is on the increase or decrease, but do 
not provide sufficient information to guide practice at a local level. 
Nearly three­quarters of all bloodstream infections (BSIs) from 
GSH, as McKay and Bamford show, were healthcare acquired; when 
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aggregated these data roughly translate into a 33% MRSA rate and a 
30% ESBL rate. Compare this with the 0% MRSA rate and 4% ESBL 
rate for community­acquired infections at the same hospital, and 
the importance of making the distinction between community­ and 
healthcare­acquired BSIs becomes obvious.
Aggregated data without context are therefore inadvertently 
detrimental to antimicrobial stewardship initiatives, as the perceived 
threat of resistance compels many prescribers to go straight for the 
‘big­gun’ antibiotics. While AMR is a very real threat to the prospects 
of treating infections, as McKay and Bamford confirm, good ol’ 
cloxacillin (a far superior drug to vancomycin in the treatment of 
S. aureus[9]) is still a perfectly suitable option in the right patient. 
Similarly, with a <5% ESBL rate for Enterobacteriaceae associated 
with community­acquired BSIs, the third­ and fourth­generation 
cephalosporins still have an important role to play.
Importantly, McKay and Bamford have indicated that their 
surveillance data are being constructively utilised at GSH, as suggested 
recommendations ‘are in line with contemporary hospital antibiotic 
recommendations’. As an example, the intensive care units (ICUs) 
account for almost three­quarters of all Acinetobacter baumannii 
bloodstream infections, supporting the decision to include colistin 
or tobramycin as empirical treatment options for ICU patients with 
suspected Gram­negative sepsis. The dissemination and utilisation of 
surveillance data is crucial if they are to impact on patient management 
and outcomes. Unfortunately this aspect is often sorely neglected, 
requiring a collaborative effort from clinical, laboratory and hospital 
staff. For the general practitioner serving the community, it would 
require close liaison with the microbiology laboratory with provision of 
practice­specific surveillance data. Local hospital AMR surveillance data 
should ideally go a step further through stratification of susceptibility 
data by ward/unit. In their study McKay and Bamford stratified by 
discipline rather than by individual wards and demonstrated some 
distinct differences in organism profile, although no major differences in 
susceptibility profiles. Ward­specific surveillance data have been shown 
to be a more useful tool for empirical antimicrobial selection, owing to 
distinct within­hospital antimicrobial susceptibility differences between 
wards/units.[10] For example, one cannot compare the cardiology ICU 
with the surgical ICU, or the haematology­oncology unit with the rest of 
the general medical unit. Nevertheless, the stratification data presented in 
this paper are illuminating and could potentially be stratified further for 
additional enhancement of antimicrobial stewardship efforts.
McKay and Bamford’s study raises some additional challenges and 
areas of focus for hospitals, laboratories and prescribers. Classification 
of infections into community v. healthcare acquired is becoming 
more difficult, and the term ‘healthcare associated’ has been widely 
used to account for an increasingly complex healthcare environment 
that includes patients from long­term care facilities, rehabilitation 
centres, dialysis centres, etc.[11,12] The definitions used in different 
studies vary considerably.[12] This lack of standardisation is a major 
stumbling block to adequate risk assessment. Similarly, the cited 
risk factors for likelihood of a multidrug­resistant organism that are 
often used to guide empirical antimicrobial selection lack specificity 
and are generally used too loosely.[13­15] Distinctive epidemiological 
criteria upon which to base antimicrobial choices are desperately 
required, and local surveillance data are crucial in addressing this 
need. Enhanced surveillance data based on standardised definitions, 
with subsequent analysis at a local (facility/practice) level, could 
potentially identify risk factors with better diagnostic accuracy. 
This would enable hospitals (facilities) to develop facility­specific 
guidelines for antimicrobial prescribing. Development of such site­
specific guidelines is particularly challenging in the private sector, 
where hospitals are governed by corporate processes and policies. 
However, hospitals are not all the same, varying significantly in 
their case mix, which influences risk factors, and crucially in their 
microbiological ‘ecosystem’. This type of enhanced surveillance would 
require substantial investment in personnel and IT infrastructure.
Laboratories face the challenge of providing accurate, reliable 
and standardised data. As indicated in McKay and Bamford’s study, 
piperacillin­tazobactam (a valuable agent) susceptibility data were 
not reported because of methodological limitations. Similarly, ESBL 
production was not tested but inferred from the cefepime result, a 
limitation acknowledged by the authors. Many laboratories would not 
use cefepime but rather ceftriaxone to infer ESBL production, whereas 
others would confirm it with phenotypic testing. It is evident that this 
methodological variance can have a major impact on the generation 
and interpretation of collated surveillance data, highlighting the 
need for some form of standardisation, if not in methods then at 
least in reporting. In the private sector there are usually two or three 
laboratories serving a hospital, each with its own subtle differences in 
practice and reporting. Ultimately the onus is on the hospital to collate 
these data and provide meaningful surveillance reports.
Notwithstanding the important antimicrobial stewardship initia­
tives undertaken by various stakeholders as part of a commitment to 
address AMR, the success of antimicrobial stewardship (if measured 
according to the aims thereof) begins with the microbiology labora­
tory. The message is very clear, as McKay and Bamford have subtly 
suggested in their concluding remarks – the onus is on diagnostic 
microbiology laboratories to provide good­quality, clinically relevant 
and stratified surveillance data.
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